Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 332-339

  Josting, Andreas ^a   Reiser, Marcel ^a   Rueffer, Ulrich ^a   Salzberger, Bernd ^a   Diehl, Volker ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033955394     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.332     Document Type: Article

References (32)

1. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1483, 1992
2. Fischer RI, Gaynor ER, Dahlberg S, et al: Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
3. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 341:1051-1054, 1993
4. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL. N Engl J Med 333:1540-1545, 1995
5. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992
6. Cabanillas F, Velasquez WS, McLauphlin P, et al: Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 25:47-50, 1988 (suppl 2)
7. Stiff JS, Dahlberg S, Forman SJ, et al: Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial. Blood 16:48-55, 1998
8. Nademannee A, O'Donnell MR, Snyder DS, et al: High-dose therapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival. Blood 85:1381-1390, 1991
9. Chopra R, McMillan AK, Linch DC, et al: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single center eight year study of 155 patients. Blood 81:1137-1145, 1993
10. Saez R, Dahlberg S, Appelbaum F, et al: Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group Study. Hematol Oncol 12:75-85, 1994
11. Phillips GL, Fay JW, Herzig RH, et al: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 75:831-838, 1990
12. Sweetenham JW, Taghipou G, Linch DC, et al: Thirty percent of adult patients with primary refractory Hodgkin's disease are progressive free at 5 years after high-dose therapy and autologous stem cell transplantation: Data from 290 patients reported to the EBMT. Blood 88:486a, 1996 (suppl 1)
13. Lazarus HM, Rowlings PA, Zhang MJ, et al: Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant registry. J Clin Oncol 17:534-545, 1999
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Cox DR: Regression models and life tables. Stat Soc 34:187-202, 1972
16. Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534, 1997
17. Frei E, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
18. Crump M, Smith AM, Brandwein J, et al: High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 11:704-711, 1993
19. Rappoport AP, Rowe JM, Kouides PA, et al: One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351-2361, 1993
20. Josting A, Katay I, Rueffer U, et al: Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289-295, 1998
21. Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent and refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801-813, 1997
22. Reece DE, Barnett MJ, Shepherd JD, et al: High-dose cyclophosphamide, carmustine, and etoposide with or without cisplatin and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451-456, 1995
23. Gianni AM, Bregni M, Siena S, et al: High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease: A 6-year update. Ann Oncol 4:889-891, 1993
24. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage chemotherapy and high-dose therapy with autografting for recurrent and refractory Hodgkin's disease. Blood 89:814-822, 1997
25. Andrè M, Henry-Amar M, Pico JL, et al: Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. J Clin Oncol 17:222-229, 1999
26. Chopra R, Goldstone AH, Pearce R, et al: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 10:1690-1697, 1992
27. Milpied N, Fielding AK, Pearce RM, et al: Allogeneic bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 14:1291-1296, 1996
28. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11:2342-2350, 1993
29. Coiffier B, Haion C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
30. Liu SY, Eary JF, Petersdorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270-3278, 1998
31. Engert A, Diehl V, Schnell R, et al: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89:403-410, 1997
32. Khouri IF, Keating M, Korbling M, et al: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998